MST1-Targeting Oligonucleotides for Lung Disorder Mechanism Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapeutics to treat lung disorders such as COPD, asthma, and other respiratory conditions, as current treatments are inadequate in addressing the underlying mechanisms of these diseases.
Innovation Solution
Compositions comprising oligonucleotides that target MST1, specifically small interfering RNA (siRNA) or antisense oligonucleotides (ASO), are administered to inhibit MST1 expression, thereby reducing MST1 mRNA and MSP levels, leading to decreased inflammation and improved lung function measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for lung disorders, then treatment is provided, but the underlying mechanisms of the diseases are not adequately addressed
Solution Approach 1:
The patent extracts and targets the specific underlying mechanism (MST1 protein) responsible for lung disorder pathology. By designing oligonucleotides that specifically bind to and inhibit MST1 mRNA translation, the treatment addresses the root cause rather than just symptoms, thereby improving reliability while maintaining adaptability to the disease mechanism.
Solution Approach 2:
The patent changes the therapeutic parameter from general lung disorder treatment to specific MST1 protein inhibition. By modifying the treatment approach to target MST1 expression at the molecular level, the therapy effectively addresses underlying disease mechanisms while providing reliable treatment outcomes for various lung disorders including COPD and asthma.
2Reliability
If oligonucleotide compositions targeting MST1 are administered, then MST1 mRNA and MSP levels are decreased, but the complexity of the treatment composition increases
Solution Approach 1:
The patent employs composite oligonucleotide structures combining multiple functional elements: 2′-O-methyl modified nucleosides for enhanced stability and binding affinity, phosphorothioate internucleoside linkages for nuclease resistance, and cholesterol moieties for cellular uptake enhancement. This composite approach achieves reliable MST1 inhibition while the modular design allows optimization of each component's contribution to efficacy and stability.
Solution Approach 2:
The oligonucleotide composition acts as an intermediary molecule that bridges the gap between external administration and intracellular MST1 mRNA inhibition. The modified nucleosides and linkages serve as mediators to protect the therapeutic agent from degradation, enhance cellular entry, and ensure specific binding to the target mRNA, thereby achieving reliable gene silencing without excessive compositional complexity.
3Reliability
If oligonucleotide compositions are administered to inhibit MST1 expression, then lung function measurements are improved, but the manufacturing and administration process becomes more complex
Solution Approach 1:
The oligonucleotide is designed as a segmented molecule with distinct functional regions: 5′ and 3′ overhangs for binding stability, a central region for MST1 mRNA complementarity, and modified nucleosides distributed throughout for enhanced properties. This segmentation allows each region to be optimized independently for its specific function while maintaining overall therapeutic efficacy and simplifying manufacturing through modular synthesis approaches.
Solution Approach 2:
The patent optimizes manufacturing ease by changing the chemical parameters of the oligonucleotide through systematic modification of nucleoside types, linkage chemistries, and appended moieties. These parameter changes enhance stability and efficacy while the standardized modification patterns across different oligonucleotide sequences facilitate scalable manufacturing and consistent quality control.
Data Source
AI summary
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.